Fibrosis in Chronic and Delayed Myocardial Infarction

Inclusion Criteria:

Cohort 1(Aortic stenosis):

• Male or female above the age of 50 years old

• Provision of informed consent prior to any study specific procedures

• 25 patients with symptomatic severe aortic stenosis (peak velocity >4.0 m/s)

• 25 patients with moderate aortic stenosis (peak velocity 3.0-4.0 m/s)

• 10 patients with mild aortic stenosis (peak velocity 2.6-2.9 m/s)

• 10 patients with aortic sclerosis (tri-leaflet thickened aortic valve with noobstruction of ventricular outflow)

• 10 healthy volunteers (no other significant co-morbidities, as assessed by the studyPI)

Cohort 2 (Chemotherapy-induced cardiotoxicity):

• Male or female over the age of 35 years with evidence of cardiotoxicity on cardiacMRI (performed as part of the Cardiac care study), at least 1 year afteranthracycline treatment.

• 10 patients over the age of 35 years (male or females) without evidence of fibrosison their 1-year scan after anthracycline treatment.

• 10 healthy volunteers (>35 years of age) with no significant co-morbidities, asassessed by the study PI.

• Provision of informed consent prior to any study specific procedures

Cohort 3 (Carcinoid syndrome):

• 30 patients with carcinoid syndrome (with or without cardiac involvement), over theage of 35 years, diagnosed as per consensus guidelines

• Provision of informed consent prior to any study specific procedures

Exclusion Criteria:

• Inability or unwilling to give informed consent.

• History of claustrophobia or feeling of inability to tolerate supine position forthe MRI scans.

• Impaired renal function with eGFR of <30 mL/min/1.73m2.

• Women who are pregnant or breastfeeding.

• Contrast allergy

• Contraindication to cardiac MRI (e.g. metallic implant or severe claustrophobia)

• Recent myocardial infarction, other known causes of cardiomyopathy/cardiac fibrosis.